View Older Stories View More Recent Stories

Feb 7, 2017 04:02PM Gilead Sciences Announces 10 Percent Increase in First Quarter 2017 Dividend
Jan 24, 2017 05:00PM Gilead Sciences to Release Fourth Quarter and Full Year 2016 Financial Results on Tuesday, February 7, 2017
Jan 20, 2017 05:51AM Gilead Sciences (GILD) MMA for Sofosbuvir/Velpatasvir/Voxilaprevir Full Validated in EU
Jan 20, 2017 05:48AM European Medicines Agency Validates Gilead’s Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
Jan 10, 2017 09:00AM Gilead Awards More Than $22 Million in Grants to Support HIV Cure Research
Jan 3, 2017 04:30PM Alessandro Riva, MD, to Join Gilead as Senior Vice President, Hematology and Oncology Therapeutic Area Head
Dec 26, 2016 05:00PM Gilead Sciences to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9
Dec 19, 2016 02:03AM Japan’s Ministry of Health, Labour and Welfare Approves Gilead’s Vemlidy® for Patients With Chronic Hepatitis B Virus Infection
Dec 8, 2016 08:11AM Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir
Nov 16, 2016 05:00PM Gilead Sciences Announces Promotion of James R. Meyers to Executive Vice President, Worldwide Commercial Operations
Nov 16, 2016 04:17PM Gilead Sciences (GILD) Announces Momelotinib Phase 3 Met Primary Endpoint in Myelofibrosis; Secondary Endpoint Missed
Nov 16, 2016 04:15PM Gilead Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis
Nov 15, 2016 05:00PM Gilead Sciences to Present at the Annual Piper Jaffray Healthcare Conference on Tuesday, November 29
Nov 14, 2016 04:32PM Gilead Sciences (GILD) Says Phase 2 Data for Selonsertib in NASH Presented at The Liver Meeting
Nov 14, 2016 04:30PM Phase 2 Data for Selonsertib in Nonalcoholic Steatohepatitis (NASH) Presented at The Liver Meeting® 2016
Nov 10, 2016 01:08PM Gilead Sciences' (GILD) Vemlidy Approved by FDA for Treatment of Chronic Hepatitis B
Nov 10, 2016 01:06PM U.S. Food and Drug Administration Approves Gilead’s Vemlidy® (Tenofovir Alafenamide) for the Treatment of Chronic Hepatitis B Virus Infection
Nov 1, 2016 04:02PM Gilead Sciences Announces Fourth Quarter 2016 Dividend
Oct 25, 2016 05:00PM Gilead Sciences to Release Third Quarter 2016 Financial Results on Tuesday, November 1, 2016
Oct 24, 2016 05:00PM Gilead Sciences to Present at the Credit Suisse 25th Annual Healthcare Conference on Monday, November 7
Oct 24, 2016 06:25AM Gilead Sciences (GILD) Announces Results from Studies of Switching HIV-1 Patients to Descovy; Results Statistically non-Inferior
Oct 24, 2016 06:24AM Gilead Presents Results from Phase 3 Studies Evaluating Switching to Descovy® (FTC/TAF)-Based Regimens from Truvada® (FTC/TDF)-Based Regimens
Oct 20, 2016 10:09AM Gilead Sciences (GILD) Announces Tipline Data from Four Sofosbuvir , Velpatasvir, Voxilaprevir Phase 3s in Genotype 1 - 6 HCV
Oct 20, 2016 10:07AM Gilead Announces SVR12 Rates From Four Phase 3 Studies of a Once-Daily, Fixed-Dose Combination of Sofosbuvir, Velpatasvir and Voxilaprevir in Treatment-Naïve and Treatment-Experienced Genotype 1-6 Ch
Oct 20, 2016 10:06AM Gilead Sciences (GILD) Announces Topline Selonsertib Phase 2 Data in NASH; Anti-Fibrotic Activity Noted
Oct 20, 2016 10:05AM Gilead Announces Top-Line Phase 2 Results for GS-4997 (Selonsertib) in Nonalcoholic Steatohepatitis (NASH), Pulmonary Arterial Hypertension (PAH) and Diabetic Kidney Disease (DKD)
Sep 27, 2016 04:08PM Gilead Sciences (GILD), WHO Enter Five-Year Visceral Leishmaniasis Collaboration
Sep 27, 2016 04:05PM Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration
Sep 21, 2016 05:01PM Gilead (GILD) Terminates Phase 2/3 Study of GS-5745 in Ulcerative Colitis Due to Futility
Sep 21, 2016 05:00PM Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
Sep 15, 2016 10:01PM Gilead Prices $5 Billion of Senior Unsecured Notes
Sep 6, 2016 01:00PM Gilead Sciences to Present at Three Upcoming Investor Conferences in September
Aug 23, 2016 09:01AM Gilead Sciences (GILD) Adds Cisco Systems' Kramer as Director
Aug 23, 2016 08:55AM Kelly A. Kramer Joins Gilead Sciences’ Board of Directors
Aug 22, 2016 11:50AM Gilead Sciences (GILD) Receives EC Marketing Approval for Truvada in HIV-1 Risk Reduction
Aug 22, 2016 11:49AM European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada® For Reducing the Risk of Sexually Acquired HIV-1
Aug 19, 2016 08:31AM Portola Pharma (PTLA) Says IndexXa MAA Accepted for Review in Europe
Jul 25, 2016 04:10PM Gilead Sciences Announces Third Quarter 2016 Dividend
Jul 22, 2016 07:17AM European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Jul 21, 2016 04:33PM Gilead Sciences (GILD) Announces Two Odefsey Phase 3b Studies Met Primary Objectives
Jul 21, 2016 04:30PM Gilead’s Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
Jul 18, 2016 05:00PM Gilead Sciences to Release Second Quarter 2016 Financial Results on Monday, July 25, 2016
Jul 8, 2016 09:02AM Ligand Pharma (LGND) Enters OmniAb Licensing Agreement with Gilead (GILD)
Jun 28, 2016 12:35PM Gilead Sciences (GILD) Receives FDA Approval for Epclusa as HCV Treatment in All Genotypes
Jun 28, 2016 10:25AM U.S. Food and Drug Administration Approves Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Jun 23, 2016 07:54AM Gilead Sciences (GILD) Granted EC Marketing Approval for Odefsey STR
Jun 23, 2016 07:53AM European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey® (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
Jun 20, 2016 08:32AM Gilead Sciences (GILD) Presents Prelim. Data from Bictegravir Phase 1
Jun 20, 2016 08:30AM Gilead Presents Preliminary Data on Bictegravir, an Investigational Integrase Strand Transfer Inhibitor for the Treatment of HIV
Jun 13, 2016 05:00PM Gilead Sciences to Present at the 36th Annual William Blair Growth Stock Conference on Tuesday, June 14
View More Recent Stories View Older Stories